Yaron Werber
Stock Analyst at TD Cowen
(1.03)
# 2,708
Out of 4,479 analysts
28
Total ratings
31.82%
Success rate
-14.24%
Average return
Main Sectors:
Top Industries:
19 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ASND Ascendis Pharma | Upgrades: Buy | $156 → $175 | $133.98 | +30.62% | 2 | Jun 25, 2024 | |
| BGNE BeiGene | Maintains: Buy | $236 → $254 | $144.89 | +75.31% | 3 | May 9, 2024 | |
| BNTX BioNTech SE | Maintains: Hold | $95 → $98 | $78.83 | +24.32% | 2 | May 7, 2024 | |
| EXEL Exelixis | Maintains: Buy | $25 → $27 | $22.25 | +21.35% | 1 | May 1, 2024 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Buy | $59 → $61 | $41.12 | +48.35% | 1 | Apr 24, 2024 | |
| STOK Stoke Therapeutics | Upgrades: Buy | n/a | $13.87 | - | 1 | Mar 26, 2024 | |
| JSPR Jasper Therapeutics | Initiates: Outperform | n/a | $23.14 | - | 1 | Mar 18, 2024 | |
| IMRX Immuneering | Downgrades: Market Perform | n/a | $1.17 | - | 2 | Mar 15, 2024 | |
| TSVT 2seventy bio | Downgrades: Market Perform | n/a | $4.05 | - | 2 | Jan 31, 2024 | |
| CLDX Celldex Therapeutics | Initiates: Outperform | n/a | $38.99 | - | 1 | Dec 20, 2023 | |
| ARGX argenx SE | Maintains: Outperform | $612 → $641 | $434.22 | +47.62% | 3 | Dec 12, 2023 | |
| GBIO Generation Bio Co. | Downgrades: Market Perform | n/a | $2.57 | - | 1 | Oct 19, 2023 | |
| FGEN FibroGen | Maintains: Market Perform | $15 → $25 | $0.77 | +3,146.33% | 1 | Feb 28, 2023 | |
| LEGN Legend Biotech | Initiates: Outperform | n/a | $46.02 | - | 1 | Nov 1, 2022 | |
| TIL Instil Bio | Downgrades: Market Perform | n/a | $10.30 | - | 2 | Nov 1, 2022 | |
| GMAB Genmab | Initiates: Market Perform | $38 | $24.85 | +52.92% | 1 | May 2, 2022 | |
| BLUE bluebird bio | Downgrades: Market Perform | n/a | $0.98 | - | 1 | Apr 6, 2022 | |
| IOBT IO Biotech | Initiates: Outperform | n/a | $1.12 | - | 1 | Nov 30, 2021 | |
| ROIV Roivant Sciences | Initiates: Outperform | n/a | $10.83 | - | 1 | Oct 26, 2021 |
Ascendis Pharma
Jun 25, 2024
Upgrades: Buy
Price Target: $156 → $175
Current: $133.98
Upside: +30.62%
BeiGene
May 9, 2024
Maintains: Buy
Price Target: $236 → $254
Current: $144.89
Upside: +75.31%
BioNTech SE
May 7, 2024
Maintains: Hold
Price Target: $95 → $98
Current: $78.83
Upside: +24.32%
Exelixis
May 1, 2024
Maintains: Buy
Price Target: $25 → $27
Current: $22.25
Upside: +21.35%
Ultragenyx Pharmaceutical
Apr 24, 2024
Maintains: Buy
Price Target: $59 → $61
Current: $41.12
Upside: +48.35%
Stoke Therapeutics
Mar 26, 2024
Upgrades: Buy
Price Target: n/a
Current: $13.87
Upside: -
Jasper Therapeutics
Mar 18, 2024
Initiates: Outperform
Price Target: n/a
Current: $23.14
Upside: -
Immuneering
Mar 15, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $1.17
Upside: -
2seventy bio
Jan 31, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $4.05
Upside: -
Celldex Therapeutics
Dec 20, 2023
Initiates: Outperform
Price Target: n/a
Current: $38.99
Upside: -
argenx SE
Dec 12, 2023
Maintains: Outperform
Price Target: $612 → $641
Current: $434.22
Upside: +47.62%
Generation Bio Co.
Oct 19, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $2.57
Upside: -
FibroGen
Feb 28, 2023
Maintains: Market Perform
Price Target: $15 → $25
Current: $0.77
Upside: +3,146.33%
Legend Biotech
Nov 1, 2022
Initiates: Outperform
Price Target: n/a
Current: $46.02
Upside: -
Instil Bio
Nov 1, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $10.30
Upside: -
Genmab
May 2, 2022
Initiates: Market Perform
Price Target: $38
Current: $24.85
Upside: +52.92%
bluebird bio
Apr 6, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $0.98
Upside: -
IO Biotech
Nov 30, 2021
Initiates: Outperform
Price Target: n/a
Current: $1.12
Upside: -
Roivant Sciences
Oct 26, 2021
Initiates: Outperform
Price Target: n/a
Current: $10.83
Upside: -